BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Firm), a clinical-stage genetic medicines firm whose non-viral lead investigational product detalimogene voraplasmid (also referred to as detalimogene, and beforehand EG-70) is in an ongoing pivotal research in sufferers with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder most cancers (NMIBC) with carcinoma in situ (Cis), at present introduced that Alex Nichols, Ph.D., Chief Technique and Operations Officer, will take part in upcoming investor conferences. Particulars of the conferences are under:
Convention: Digital Residents JMP Hematology & Oncology Summit
Date: Monday, December 2, 2024
Time: 10:00 a.m. ET
Format: Company Presentation
Convention: Piper Sandler thirty sixth Annual Healthcare Convention
Date: Tuesday, December 3, 2024
Time: 3:00 p.m. ET
Format: Fireplace Chat
A stay webcast of those shows may be accessed beneath the Buyers part of the enGene web site at www.engene.com and might be archived there for 90 days.
About enGene
enGene is a clinical-stage biotechnology firm mainstreaming genetic medicines via the supply of therapeutics to mucosal tissues and different organs, with the objective of making new methods to deal with illnesses with excessive scientific wants. enGene’s lead program is detalimogene voraplasmid, (also referred to as detalimogene, and beforehand EG-70) for sufferers with Non-Muscle Invasive Bladder Most cancers (NMIBC) “ a illness with a excessive scientific burden. Detalimogene is being evaluated within the ongoing multi-cohort LEGEND Part 2 research, which features a pivotal cohort learning detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive sufferers with carcinoma in situ (Cis). Detalimogene was developed utilizing enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which permits penetration of mucosal tissues and supply of a variety of sizes and forms of cargo, together with DNA and varied types of RNA. For extra data, go to enGene.com.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241125221097/en/
For media contact: media@engene.com
For investor contact: traders@engene.com
Supply: enGene Holdings Inc.
